Pharma BD Deal Intelligence

Eureka Therapeutics, Inc. / JW Therapeutics

2026 · Licensing/Option · $110M · Pending

JW Therapeutics agreed to transfer regional (China) rights to ARTEMIS-based AFP- and GPC3-targeted cell therapies back to Eureka Therapeutics' Hong Kong subsidiary, exiting the two solid tumor programs. Eureka pays USD 10 million upfront, with JW eligible for up to USD 100 million in additional commercial milestones contingent on a qualifying third-party transaction and subsequent sales targets. JW also receives 10% of proceeds attributable to the transferred products and territory from qualifying third-party agreements entered by Eureka within 24 months of closing, with revenue sharing continuing six years after each qualifying transaction.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →